Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

[Novel migraine treatment with CGRP-related monoclonal antibodies].

Tytuł:
[Novel migraine treatment with CGRP-related monoclonal antibodies].
Autorzy:
Shibata M; Department of Neurology, Tokyo Dental College Ichikawa General Hospital.
Źródło:
Rinsho shinkeigaku = Clinical neurology [Rinsho Shinkeigaku] 2020 Oct 24; Vol. 60 (10), pp. 668-676. Date of Electronic Publication: 2020 Sep 05.
Typ publikacji:
Journal Article; Review
Język:
Japanese
Imprint Name(s):
Publication: April 1963-: Tōkyō : Nihon Shinkei Gakkai
Original Publication: Tōkyō : Nihon Rinshō Shinkei Gakkai, 1960-
MeSH Terms:
Molecular Targeted Therapy*
Antibodies, Monoclonal/*administration & dosage
Calcitonin Gene-Related Peptide/*immunology
Calcitonin Gene-Related Peptide Receptor Antagonists/*administration & dosage
Migraine Disorders/*drug therapy
Migraine Disorders/*genetics
Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; Drug Development ; Humans ; Mice ; Migraine Disorders/prevention & control ; Receptors, Calcitonin Gene-Related Peptide/immunology
Contributed Indexing:
Keywords: antibody therapy; calcitonin gene-related peptide (CGRP); intractable headache; migraine; trigeminal system
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Calcitonin Gene-Related Peptide Receptor Antagonists)
0 (Receptors, Calcitonin Gene-Related Peptide)
0 (fremanezumab)
55KHL3P693 (galcanezumab)
8202AY8I7H (eptinezumab)
JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
Entry Date(s):
Date Created: 20200907 Date Completed: 20201123 Latest Revision: 20220420
Update Code:
20240105
DOI:
10.5692/clinicalneurol.cn-001469
PMID:
32893246
Czasopismo naukowe
Migraine is a common and debilitating neurological disorder characterized by recurrent attacks of moderate to severe throbbing headache accompanied by nausea, vomiting and photophobia/phonophobia. Because of its high prevalence, migraine causes a considerable financial burden on the society as well as impaired quality of life in individual patients. Scientific evidence shows that migraine is a quite complex neurological disorder that involves not only the trigeminovascular and autonomic systems but also the hypothalamus and cerebral cortex. Calcitonin gene-related peptide (CGRP) was originally discovered as a 37-amino acid neuropeptide derived from a calcitonin gene splicing variant. CGRP is found to be expressed in trigeminal ganglion neurons. Much attention has been attracted to this molecule since CGRP was found to be released from trigeminal terminals in animal migraine models. Subsequent studies demonstrated that CGRP administration induced migraine-like headache attacks specifically in migraineurs, thus highlighting a pivotal role of CGRP in the development of migraine attacks. Several CGRP receptor antagonists were shown to be efficacious for the treatment of acute migraine. Among them, telcagepant, was shown to exert a significant migraine prophylactic action as well. Nevertheless, the development of most of these agents were discontinued due to hepatotoxicity. Currently, newer CGRP receptor antagonists are being developed. On the other hand, monoclonal antibodies targeting CGRP and its receptor showed consistent efficacy for migraine prophylaxis with excellent safety profiles in Phase III clinical trials. Furthermore, emerging data support the long-term safety and efficacy of these antibodies. In this review article, the development and perspective of anti-migraine therapeutic strategies using CGRP-related antibodies are discussed.
Erratum in: Rinsho Shinkeigaku. 2020;60(10):733. (PMID: 33100296)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies